GLSI
HealthcareGreenwich LifeSciences, Inc.
$21.21
+$1.74 (+8.94%)
Jan 5, 2026
Price History (1Y)
Analysis
Greenwich LifeSciences, Inc. (GLSI) is a biotechnology company within the healthcare sector. With a market capitalization of $293.85M and 4 employees, it operates on a relatively small scale compared to larger industry players. The company's financial health indicates significant losses. Net income for the trailing twelve months (TTM) stands at -$19,475,704, with an EBITDA of -$19,584,406 and Free Cash Flow of -$1,357,228. Gross Margin, Operating Margin, and Profit Margin all register 0.0%, indicating minimal profitability. Returns on Equity and Assets are negative at -543.4% and -254.2%, respectively. The company maintains a Current Ratio of 2.35. Valuation metrics suggest a negative forward P/E ratio of -25.87 and an EV/EBITDA of -13.58, indicating significant financial strain. Price to Book stands at 134.24.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Visit website →Key Statistics
- Market Cap
- $293.85M
- P/E Ratio
- N/A
- 52-Week High
- $30.82
- 52-Week Low
- $7.78
- Avg Volume
- 302.92K
- Beta
- 1.44
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 4